Aspire Biopharma Holdings, Inc. cash flow statement ASBP

In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Aspire Biopharma Holdings, Inc. used $2.1 million of cash from operations, down 85.5% from the same quarter a year earlier.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Operating
Stock-based compensation
0
0
0
-99.9%
0
0
0
14
—
—
Operating cash flow
-7
-147.1%
-2
-85.5%
-3
-73.5%
-1
-293.5%
-1
-122.7%
-1
-1927.4%
-2
-807.7%
0
+407.2%
-0
-296.7%
Investing
Investing cash flow
—
—
—
—
—
—
—
0
0
-100.0%
Financing
Stock buybacks
—
—
—
—
—
—
—
0
0
-100.0%
Financing cash flow
19
+518.7%
8
8
+155.0%
-0
+96.6%
3
+477.9%
0
-100.0%
3
+1250.8%
-0
-416.0%
0
+177.8%
Change in cash
Net change in cash
12
+15353.6%
6
+653.4%
5
+261.4%
-1
-337173.9%
2
+1494.5%
-1
-500.3%
1
+837.4%
—
—
Shareholder returns
Returned to shareholders
—
—
—
—
—
—
—
0
0
Ratios
Stock-based compensation to revenue
—
228.34%
47.28%
0.00%
0.00%
—
—
—
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ASBP (Nasdaq), ASBPW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Estero, FL
SEC filer status
, Emerging growth company
SEC CIK
1847345
Former names
Aspire Biopharma Holdings, Inc. (until Sep 9, 2026); PowerUp Acquisition Corp. (until Feb 19, 2025)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.